- Home
- MOBX vs DYAI Comparison
MOBX vs DYAI Comparison
Compare MOBX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- DYAI
- Stock Information
- Founded
- MOBX 2020
- DYAI 1979
- Country
- MOBX United States
- DYAI United States
- Employees
- MOBX N/A
- DYAI N/A
- Industry
- MOBX
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOBX
- DYAI Health Care
- Exchange
- MOBX Nasdaq
- DYAI Nasdaq
- Market Cap
- MOBX 29.9M
- DYAI 31.5M
- IPO Year
- MOBX N/A
- DYAI 2004
- Fundamental
- Price
- MOBX $0.58
- DYAI $1.67
- Analyst Decision
- MOBX
- DYAI Strong Buy
- Analyst Count
- MOBX 0
- DYAI 1
- Target Price
- MOBX N/A
- DYAI $6.00
- AVG Volume (30 Days)
- MOBX 132.8K
- DYAI 44.6K
- Earning Date
- MOBX 11-29-2024
- DYAI 11-12-2024
- Dividend Yield
- MOBX N/A
- DYAI N/A
- EPS Growth
- MOBX N/A
- DYAI N/A
- EPS
- MOBX N/A
- DYAI N/A
- Revenue
- MOBX $3,921,000.00
- DYAI $3,364,548.00
- Revenue This Year
- MOBX N/A
- DYAI $2.04
- Revenue Next Year
- MOBX N/A
- DYAI $110.34
- P/E Ratio
- MOBX N/A
- DYAI N/A
- Revenue Growth
- MOBX 214.69
- DYAI 13.82
- 52 Week Low
- MOBX $0.55
- DYAI $0.93
- 52 Week High
- MOBX $12.50
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- MOBX 31.47
- DYAI 80.91
- Support Level
- MOBX $0.60
- DYAI $1.08
- Resistance Level
- MOBX $0.68
- DYAI $1.80
- Average True Range (ATR)
- MOBX 0.07
- DYAI 0.15
- MACD
- MOBX -0.00
- DYAI 0.06
- Stochastic Oscillator
- MOBX 0.00
- DYAI 83.33
About MOBX Mobix Labs Inc.
Mobix Labs Inc is a fabless semiconductor company developing disruptive next generation wireless and connected solutions that are designed to cater to a broad range of applications in markets including 5G infrastructure, satellite communications, automotive, consumer electronics, e-mobility, healthcare, infrastructure and defense.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.